AMRI signs preferred provider agreement with BioPontis
The aim is to identify promising early stage product opportunities
AMRI, a global contract services organisation based in Albany, US, will work with BioPontis Alliance in a preferred provider agreement to support BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research organisations.
AMRI will provide its expertise in small molecule discovery, development, and manufacturing.
The aim is to identify promising early stage product opportunities and create a preferred network of contract research organisations to develop these products to attract pharmaceutical company licensing partners.
BioPontis Alliance has formed research alliances with a consortium of leading universities and research institutions as it searches for innovative science with the potential to be translated into new treatments for cancer, neurology, inflammation, and infectious diseases.
BioPontis Alliance currently has agreements with New York University, Columbia University, Memorial Sloan-Kettering Cancer Center, University of Pennsylvania, University of North Carolina (Chapel Hill), University of Virginia, University of Kansas, Oregon Health and Sciences University, Thomas Jefferson University and the University of Florida.
The firm has also entered into preferred partnership agreements with pharmaceutical companies such as Janssen Biotech, Pfizer and Merck.
AMRI ceo Thomas D'Ambra, said: ‘Building on the recently announced collaborations with the National Institutes of Health and others, the relationship with BioPontis Alliance is another example of AMRI's leading ability to contribute significant value in the discovery and development of the medicines of the future.
‘Given the outreach by a number of pharmaceutical companies to the outside for innovative new approaches to treating disease, the BioPontis Alliance may fill an important need for the industry in identifying new therapeutic agents and approaches to treating unmet medical needs.’
Richard Basile, ceo of BioPontis Alliance, added: ‘It is important we bring together the best partners to support the success of our new business model. For many reasons, and after significant due diligence, AMRI was the obvious partner of choice.’
